Breaking News Instant updates and real-time market news.

PRTA

Prothena

$50.79

-3.55 (-6.53%)

, NTRP

Neurotrope

$18.60

-0.7 (-3.63%)

04:55
03/22/17
03/22
04:55
03/22/17
04:55

Oppenheimer to hold a conference

27th Annual Healthcare Conference is being held in New York on March 21-22.

PRTA

Prothena

$50.79

-3.55 (-6.53%)

NTRP

Neurotrope

$18.60

-0.7 (-3.63%)

E

Eni SpA

$32.07

0.24 (0.75%)

VHC

VirnetX

AMGN

Amgen

$166.85

-2.39 (-1.41%)

SRDX

Surmodics

$23.70

-0.55 (-2.27%)

VSTM

Verastem

$1.54

-0.08 (-4.94%)

AFMD

Affimed NV

$2.45

-0.15 (-5.77%)

CBAY

CymaBay

$3.91

-0.15 (-3.69%)

HUM

Humana

$213.55

-1.85 (-0.86%)

AVXL

Anavex

$5.68

-0.36 (-5.96%)

PTLA

Portola Pharmaceuticals

$37.98

-2.44 (-6.04%)

GNMX

Aevi Genomics Medicine

$1.75

-0.46 (-20.81%)

NTLA

Intellia Therapeutics

$13.05

-1.3 (-9.06%)

TLGT

Teligent

$7.36

-0.37 (-4.79%)

AVGR

Avinger

$1.75

-0.15 (-7.89%)

HLTH

Nobilis Health

$1.60

-0.1 (-5.88%)

CHE

Chemed

$185.65

-0.49 (-0.26%)

OVAS

OvaScience

BTX

BioTime

$3.25

-0.21 (-6.07%)

CPSI

Computer Programs

$27.95

-0.4 (-1.41%)

HCA

HCA Healthcare

$82.62

-1.3 (-1.55%)

AMED

Amedisys

$49.32

-0.93 (-1.85%)

AERI

Aerie Pharmaceuticals

$45.30

-2.9 (-6.02%)

CUR

Neuralstem

$5.35

-0.36 (-6.30%)

  • 22

    Mar

  • 23

    Mar

  • 23

    Mar

  • 27

    Mar

  • 28

    Mar

  • 28

    Mar

  • 29

    Mar

  • 29

    Mar

  • 29

    Mar

  • 31

    Mar

  • 01

    Apr

  • 19

    Apr

  • 20

    Apr

  • 25

    Apr

  • 30

    May

  • 06

    Jun

  • 24

    Jun

  • 19

    Jul

PRTA Prothena
$50.79

-3.55 (-6.53%)

01/30/17
DBAB
01/30/17
NO CHANGE
DBAB
Deutsche sees 'lots to like' for Biotechnology in 2017
Deutsche Bank analyst Andrew Peters says that while pricing headwinds are likely to dominate the near-term conversation, there is a "lot to like" in 2017 in the Biotechnology space. Fundamentals, when focusing on the longer term, remain strong and present an opportunity, Peters tells investors in a research note. He lists Exelixis (EXEL), BioMarin (BMRN), Prothena (PRTA) and Neurocrine (NBIX) as among his favored stocks for 2017.
12/20/16
RHCO
12/20/16
INITIATION
Target $75
RHCO
Buy
Prothena initiated with a Buy at SunTrust
SunTrust initiated Prothena with a Buy and a $75 price target.
01/30/17
OPCO
01/30/17
NO CHANGE
Target $70
OPCO
Outperform
Prothena price target lowered to $70 from $77 at Oppenheimer
Oppenheimer analyst Jay Olson lowered his price target for Prothena (PRTA) to $70 from $77 ahead of Q4 earnings. Nonetheless, the analyst reiterates an Outperform rating on the shares, saying that his optimism is fueled by the broad pipeline that is based on an antibody discovery platform. Olson views the technology as partially validated by the company's partnership with Roche (RHHBY) for PRX002, which increases his confidence in the entire pipeline.
03/01/17
NOMU
03/01/17
INITIATION
Target $87
NOMU
Buy
Prothena initiated with a Buy at Nomura
Nomura initiated Prothena with a Buy and a $87 price target.
NTRP Neurotrope
$18.60

-0.7 (-3.63%)

E Eni SpA
$32.07

0.24 (0.75%)

11/02/16
JPMS
11/02/16
DOWNGRADE
JPMS
Underweight
Eni SpA downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Christyan Malek downgraded Eni SpA to Underweight.
01/17/17
JEFF
01/17/17
UPGRADE
JEFF
Buy
Eni SpA upgraded to Buy from Hold at Jefferies
Jefferies analyst Jason Gammel upgraded Eni SpA (E) to Buy from Hold, calling the stock one of the best plays on this momentum in the integrated oil sector, whose fundamental conditions he sees as arguably the most favorable since 2012. The analyst, who raised his price target on Eni to EUR 18, also sees Chevron (CVX), Marathon Oil (MRO) and Shell (RDS.A) as well positioned given the improved conditions for the integrated oil sector.
12/05/16
MSCO
12/05/16
UPGRADE
MSCO
Equal Weight
Eni SpA upgraded to Equal Weight from Underweight at Morgan Stanley
01/10/17
EXAN
01/10/17
UPGRADE
EXAN
Neutral
Eni SpA upgraded to Neutral from Underperform at Exane BNP Paribas
VHC VirnetX

AMGN Amgen
$166.85

-2.39 (-1.41%)

03/17/17
JPMS
03/17/17
NO CHANGE
JPMS
Overweight
Amgen data do not justify Medicines selloff, says JPMorgan
JPMorgan analyst Jessica Fye believes today's cholesterol data from Amgen (AMGN) do not justify the downward move in shares of The Medicines Co. (MDCO). The analyst sees a "clear clinical benefit" from Amgen's Repatha, which she thinks support the likelihood of clinical success and value for Medicines' inclisiran. The analyst remains comfortable with her 70% probability of success and $1.6B peak sales forecast for inclisiran. Fye keeps an Overweight rating on Medicines and believes the 18% selloff today is overdone.
03/17/17
PIPR
03/17/17
NO CHANGE
PIPR
Overweight
Amgen weakness a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer recommends using today's weakness in shares of Amgen as a buying opportunity. The analyst believes Amgen can still turn Repatha into a $5B-plus product and he reiterates an Overweight rating on the shares.
03/17/17
NEED
03/17/17
NO CHANGE
Target $25
NEED
Strong Buy
Needham calls Esperion selloff on Amgen data 'counter-intuitive'
Needham analyst Chad Messer believes the selloff in shares of Esperion Therapeutics (ESPR) based on Amgen's (AMGN) Repatha's data is "counter-intuitive." The fact that there was a statistically significant benefit confirms that LDL reductions prevent heart attacks and strokes, Messer tells investors in a research note. Bempedoic acid will likely be priced more in line with other oral cholesterol therapies, which makes the value debate for PCSK9 drugs a positive for Esperion, not a negative, the analyst contends. The analyst keeps a Buy rating on Esperion with a $25 price target.
03/20/17
JPMS
03/20/17
NO CHANGE
JPMS
Neutral
Esperion LDL-C lowering endpoint news a clear positive, says JPMorgan
After Esperion (ESPR) announced that the FDA confirmed that the bempedoic acid phase 3 program is adequate to support approval of an LDL-C lowering indication prior to outcomes data, JPMorgan analyst Jessica Fye said some expectation for this type of update "started to come into the stock" after Amgen's (AMGN) release of the FOURIER trial top-line results on last Friday. Still, the news is a clear positive for Esperion as it lifts one of the largest overhangs on the stock over the past 18 months. Fye, who now sees the potential for approval of bempedoic acid in 2020, keeps a Neutral rating on Esperion shares.
SRDX Surmodics
$23.70

-0.55 (-2.27%)

05/03/16
BRRR
05/03/16
NO CHANGE
Target $30
BRRR
Outperform
SurModics price target raised to $30 from $27 at Barrington
Barrington analyst Michael Petusky raised his price target on SurModics to $30 from $27 following the company's beat and raise report for the second quarter. The firm maintains an Outperform rating on the stock.
11/21/16
BRRR
11/21/16
DOWNGRADE
BRRR
Market Perform
SurModics downgraded to Market Perform from Outperform at Barrington
11/21/16
11/21/16
DOWNGRADE

Market Perform
SurModics downgraded to Market Perform at Barrington
As previously reported, Barrington analyst Michael Petusky downgraded SurModics to Market Perform from Outperform after the company's guidance for FY17 was meaningfully below consensus and his expectations. The analyst, who said he continues to like "much of what he sees" at SurModics, said he would revisit his rating if shares weaken "materially" from current levels.
10/06/16
SIDC
10/06/16
DOWNGRADE
SIDC
Neutral
SurModics downgraded to Neutral from Buy at Sidoti
VSTM Verastem
$1.54

-0.08 (-4.94%)

AFMD Affimed NV
$2.45

-0.15 (-5.77%)

01/04/17
OPCO
01/04/17
NO CHANGE
Target $10
OPCO
Outperform
Affimed NV price target lowered to $10 from $19 at Oppenheimer
Oppenheimer analyst Hartaj Singh lowered his price target for Affimed NV to $10 from $19 on valuation methodology. Nonetheless, with no fundamental changes to the story and "compelling" early-stage data for its lead products, the analyst believes the company's current valuation and upcoming inflection points present an "intriguing entry point" for biotech investors. He reiterates an Outperform rating on the shares.
08/12/16
LEER
08/12/16
DOWNGRADE
Target $3
LEER
Market Perform
Affimed NV downgraded to Market Perform from Outperform at Leerink
Leerink analyst Michael Schmidt downgraded Affimed NV to Market Perform and cut his price target for the shares to $3 from $8 following the company's Q2 results.
05/19/16
LEER
05/19/16
DOWNGRADE
Target $8
LEER
Market Perform
Affimed NV downgraded to Market Perform from Outperform at Leerink
Yesterday, Leerink analyst Michael Schmidt downgraded Affimed NV to Market Perform from Outperform, stating that the company's two clinical stage product candidates are progressing slowly while the competitive landscape intensifies. The analyst, who thinks the stock will remain range-bound, likely until 2017, set an $8 target on the shares.
04/12/16
04/12/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. NetSuite (N) initiated with an Overweight at Mitsubishi UFJ by analyst Stephen Bersey, who expects the company to increase its subscription revenue by 30% in 2016 and 31% in 2017. 2. QEP Resources (QEP) initiated with an Overweight at JPMorgan with analyst Gabriel Daoud saying the company's positions in Bakken and Permian are underappreciated and can drive oil growth for years to come. 3. Rubicon Project (RUBI) initiated with a Buy at Citi by analyst Mark Kelley, who said Rubicon is his top pick in the U.S. SMID Internet space. Kelley said that the company is best positioned to benefit from programmatic growth with its full-stack offering. 4. Senseonics (SENS) initiated with a Buy at BTG and Canaccord and an Outperform at Leerink and Raymond James. 5. Affimed Therapeutics (AFMD) initiated with an Outperform at BMO Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CBAY CymaBay
$3.91

-0.15 (-3.69%)

01/30/17
HCWC
01/30/17
UPGRADE
Target $6
HCWC
Buy
CymaBay upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright analyst Ed Arce upgraded CymaBay to Buy citing the potential for up to $200M of milestone payments from Kowa, the company's new U.S. partner for arhalofenate, and a more positive view of the potential of MBX-8025 to treat Primary Biliary Cirrhosis. The analyst raised his price target for the shares to $6 from $2.50.
07/01/16
ROTH
07/01/16
INITIATION
Target $4
ROTH
Buy
CymaBay coverage resumed with a Buy at Roth Capital
Roth Capital analyst Sa'ar Yaniv resumed coverage of CymaBay with a Buy rating and $4 price target.
06/01/16
HCWC
06/01/16
DOWNGRADE
Target $2.25
HCWC
Neutral
CymaBay downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce downgraded CymaBay Therapeutics to Neutral saying that while the primary biliary cholangitis study stopped early for strong efficacy, increases in transaminases renders the overall result uncertain. The analyst has a $2.25 price target for the shares.
11/16/16
PIPR
11/16/16
NO CHANGE
Target $5
PIPR
Overweight
CymaBay price target raised to $5 from $4 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for CymaBay Therapeutics to $5 after the company gave two oral presentations on MBX-8025. In the Phase II study, both 50mg and 200mg MBX-8025 significantly reduced Alkaline Phosphatase, but three patients had dose-dependent transaminase elevations, Tenthoff tells investors in a research note. To analyst sees increased value for MBX-8025 and reiterates an Overweight rating on CymaBay.
HUM Humana
$213.55

-1.85 (-0.86%)

02/07/17
CANT
02/07/17
NO CHANGE
Target $186
CANT
Neutral
Humana transferred with a Neutral at Cantor
Cantor Fitzgerald analyst Steven Halper assumed coverage of Humana with a Neutral rating and $186 price target.
02/09/17
JPMS
02/09/17
NO CHANGE
JPMS
JPMorgan doesn't expect big moves for Anthem, Cigna shares
Given the low perceived probability of a merger approval, shares of Anthem (ANTM) and Cigna (CI) are unlikely to move materially today, JPMorgan analyst Gary Taylor tells investors in a research note. He also sees "little plausible grounds" for the companies to appeal the court's decision. The merger agreement states that Anthem owes Cigna a $1.85B taxable breakup fee upon a regulatory block, which this judgment clearly represents, Taylor contends. The analyst continues to believe that Anthem and Cigna could have potential interest in acquiring Humana (HUM).
02/15/17
PIPR
02/15/17
NO CHANGE
Target $231
PIPR
Overweight
Deal termination positive for Humana, says Piper Jaffray
Piper Jaffray analyst Sarah James believes Humana (HUM) is in a stronger position today than when Aetna (AET) announced its merger offer. The analyst views the deal termination as a positive since she feels Humana is more valuable than the merger price. James keeps an Overweight rating on the shares with a $231 price target.
02/15/17
FBCO
02/15/17
NO CHANGE
Target $220
FBCO
Outperform
Humana price target raised to $220 from $208 at Credit Suisse
Credit Suisse analyst Scott Fidel raised his price target for Humana (HUM) to $220 from $208 following the termination of the company's proposed merger with Aetna (AET). The analyst believes Humana offers investors some "new sweets" post "Valentine's Day Break-up," including 2017 EPS guidance above the Street view, an increase in its dividend, a new share buyback, and a full exit from its beleaguered public exchange business in 2018. The analyst reiterates an Outperform rating on Humana's shares.
AVXL Anavex
$5.68

-0.36 (-5.96%)

03/29/16
FBRC
03/29/16
INITIATION
Target $10
FBRC
Outperform
Anavex initiated with an Outperform at FBR Capital
FBR Capital analyst Christopher James started Anavex Life Sciences with an Outperform rating and $10 price target.
02/07/17
NBLE
02/07/17
INITIATION
Target $16
NBLE
Anavex initiated with a Buy at Noble Financial
Noble Financial analyst Kumaraguru Raja initiated Anavex with a Buy and a $16 price target. The lead product candidate, ANAVEX 2-73, is on path for a Phase 2/3 in Alzheimer's disease and a Phase 2 study in Rett's Syndrome. In previous trials, ANAVEX 2-73 has exhibited a high affinity and selection to sigma-1 receptors, and has shown synergistic action with other receptors, such as Muscarinic and N-methyl-D-aspartate in clinical trials. The drug has also displayed a favorable side effect profile, which can be beneficial to patients and advantageous when compared to current treatments. Anavex has received a grant from the International Rett Syndrome Foundation for at least $600,000, based on promising animal data. This grant is expected to cover most of the cost of the planned Phase 2 clinical trial of ANAVEX 2-73 in Rett syndrome.
02/07/17
NBLE
02/07/17
INITIATION
Target $16
NBLE
Buy
Anavex initiated with a Buy at Noble Financial
Noble Financial initiated Anavex with a Buy and a $16 price target.
11/28/16
MAXM
11/28/16
NO CHANGE
Target $15
MAXM
Buy
Anavex may be targeting 'ideal approach' to Alzheimer's disease, says Maxim
After Eli Lilly's (LLY) solanezumab failed its third Phase 3 study in early-stage Alzheimer's disease, Maxim analyst Jason McCarthy noted that Anavex's (AVXL) 2-73 targets the disease "more broadly upstream" to restore proper CNS cell function and has shown "promising early data." While too soon to draw any firm conclusions, given the lessons learned from failures in pursuit of other avenues, Anavex "may be on the right track" by looking upstream, said McCarthy, who keeps a Buy rating and $15 price target on the stock.
PTLA Portola Pharmaceuticals
$37.98

-2.44 (-6.04%)

03/01/17
WBLR
03/01/17
NO CHANGE
WBLR
Outperform
William Blair 'cautiously optimistic' on FDA approval for Portola
Following Portola Pharmaceuticals' Q4 results, William Blair analyst John Sonnier says he's "cautiously optimistic" on the potential for regulatory approval of betrixaban on June 24. The analyst believes approval would be worth $60 per share. Since the initial disclosure of the failed Phase III primary endpoint, the "evolution of the betrixaban story has been highly supportive," Sonnier tells investors in a research note. He believes the full data presentation at the International Society on Thrombosis and Haemostasis annual meeting in May and further sub-study results presented at the American Heart Association Scientific Sessions in November were "highly supportive of the overall benefit from betrixaban therapy." The analyst keeps an Outperform rating on Portola.
02/24/17
OPCO
02/24/17
UPGRADE
Target $40
OPCO
Outperform
Portola Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer
Oppenheimer analyst Jay Olson upgraded Portola Pharmaceuticals to Outperform saying no FDA advisory panel is a ''clear positive" for betrixaban. The analyst is also "increasingly optimistic" about growth of the Factor Xa inhibitor class. He raised his price target for Portola shares to $40 from $28.
02/17/17
SBSH
02/17/17
NO CHANGE
Target $39
SBSH
Buy
Portola Pharmaceuticals price target raised to $39 from $32 at Citi
Citi analyst Yigal Nochomovitz raised his price target for Portola Pharmaceuticals to $39 saying his analysis indicates that the FDA no longer requesting an advisory panel for betrixaban is good news. The analyst raised the approval probability of the drug to 85% from 75%. Priority review and no panel is tied to a 94% approval probability, substantially higher than the 67% approval probability for priority review with a panel, Nochomovitz tells investors in a research note, citing his analysis. He keeps a Buy rating on Portola.
03/09/17
FBCO
03/09/17
NO CHANGE
Target $39
FBCO
Neutral
Portola Pharmaceuticals price target raised to $39 from $29 at Credit Suisse
Credit Suisse analyst Vamil Divan raised his price target for Portola Pharmaceuticals to $39 from $29, given quarterly results, the recent HealthCare Royalty Partners deal and increasing probability of success for betrixaban. The analyst reiterates a Neutral rating on the shares given the strong move the stock has had and ahead of the American College of Cardiology Meeting.
GNMX Aevi Genomics Medicine
$1.75

-0.46 (-20.81%)

02/22/17
JMPS
02/22/17
INITIATION
JMPS
Outperform
Aevi Genomics Medicine coverage assumed with an Outperform at JMP Securities
JMP Securities analyst Jason Butler assumed coverage of Aevi Genomics Medicine with an $8 price target and an Outperform rating.
03/20/17
PIPR
03/20/17
NO CHANGE
Target $7
PIPR
Overweight
Aevi Genomics Medicine price target lowered to $7 from $14 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target on Aevi Genomics Medicine to $7 from $14 after the company announced that a trial of AEVI-001 in adolescents with ADHD did not meet the primary endpoint of the study. However, the Phase 3 trial showed a numerical improvement on the primary endpoint and a pre-specified sub-group analysis showed 30% or greater ADHD-RS-5 improvement, which he believes shows activity of AEVI-001. The analyst, who expects Aevi to conduct a longer Phase 2 study in younger patients at higher doses, pushed out his expectation for AEVI-001 approval by one year to 2021 and keeps an Overweight rating on the stock.
03/21/17
JEFF
03/21/17
DOWNGRADE
Target $2.5
JEFF
Hold
Aevi Genomics Medicine downgraded to Hold from Buy at Jefferies
Jefferies analyst Matthew Andrews downgraded Aevi Genomics Medicine to Hold after AEVI-001 didn't achieve significance on primary endpoint in ADHD. The analyst sees shares being range-bound and cut his price target for the stock to $2.50 from $10.
01/05/17
JEFF
01/05/17
NO CHANGE
JEFF
Celgene, Alkermes among Jefferies' top 2017 Biotech picks
Jefferies' Biotechnology equity research team laid out their top picks for 2017. Following a volatile two years, the biotech space seeks to achieve "greater equilibrium" in 2017, the analysts write in a research note. They cite increasing competition, slowing volumes, and ramping payer leverage as reasons to remain selective when picking stocks this year and beyond. Among large-caps, Jefferies likes Celgene (CELG) for its "best-in-class growth" and sees limited downside in Gilead (GILD) shares. In the mid-cap space, the firm favors Alkermes (ALKS) given the prospects for Vivitrol and Aristada and a "strong" neurology pipeline as well as Vertex (VRTX). Jefferies' top small-cap picks include Aevi Genomics Medicine, Alder Biopharmaceuticals (ALDR), AMAG Pharmaceuticals (AMAG), DBV Technologies (DBVT), Immunomedics (IMMU), Ignyta (RXDX), Karyopharm (KPTI), RA Pharmaceuticals (RARX), TherapeuticsMD (TXMD) and Xenon Pharmaceuticals (XENE).
NTLA Intellia Therapeutics
$13.05

-1.3 (-9.06%)

09/28/16
JANY
09/28/16
INITIATION
Target $29
JANY
Buy
Intellia Therapeutics initiated with a Buy at Janney Capital
Janney Capital analyst Roy Buchanan initiated Intellia Therapeutics with a Buy and a $29 fair value estimate.
02/15/17
JEFF
02/15/17
NO CHANGE
JEFF
Patent ruling best case for Editas Medicine, says Jefferies
Jefferies analyst Gena Wang views the United States Patent and Trademark Office's judgment of "no interference-in-fact" for the CRISPR/Cas9 interference motion phase as the "best case" for Editas Medicine (EDIT), Broad Institute's licensee. The analyst sees three choices for The University of California, which has CRISPR Therapeutics (CRSP) and Intellia Therapeutics (NTLA) as licensees: Appeal, seek second interference, or discuss a settlement. Wang sees cross-licensing as the likely eventual path taken by both parties. CRISPR and Intellia could license from Editas the use of CRISPR in eukaryotic cells, while Editas could license from the two companies the use of single guide and tracrRNA, the analyst tells investors in a research note. She believes a royalty could be in the mid-single-digit range. Shares of Editas are up 33% to $24.99 in afternoon while CRISPR is down 13% to $15.05 and Intellia is down 11% to $12.26.
02/16/17
PIPR
02/16/17
NO CHANGE
Target $21
PIPR
Overweight
Piper's Schimmer calls CRISPR selloff 'major overreaction'
Piper Jaffray analyst Joshua Schimmer views yesterday's selloff in shares of CRISPR Therapeutics (CRSP) as a "major overreaction." The stock closed yesterday down 8%, or $1.36, to $15.90 after the patent office did not allow the patent interference with UC Berkeley versus Broad Institute over a Crispr/Cas-9 patent. Now that it's deemed patentable, CRISPR will move forward to get its own claims issued and likely move towards a second interference, Schimmer tells investors in a research note. CRISPER and Intellia Therapeutics (NTLA) are essentially litigation partners against the Broad, and now have the chance to win by knocking out Editas Medicine's (EDIT) single-guide tracr patent or by showing it was the first to invent and reduce to practice the application in eukaryotes, the analyst contends. Schimmer says he can't understand why Editas' valuation is higher than CRISPR's. He believes it should be the opposite. The analyst keeps an Overweight rating on CRISPR with a $21 price target.
02/16/17
JEFF
02/16/17
NO CHANGE
Target $33
JEFF
Buy
Intellia IP position largely unchanged after ruling, says Jefferies
After management hosted a conference call, Jefferies analyst Gena Wang says Intellia Therapeutics (NTLA) remains well positioned for potential broad intellectual property issuance given claims already deemed allowable by patent examiners. Despite yesterday's "no interference" ruling, the company's U.S. IP position is largely unchanged, Wang tells investors in a research note. She continues to believe cross-licensing could be the eventual path for both Intellia and Editas Medicine (EDIT). The analyst has a Buy rating on Intellia with a $33 price target.
TLGT Teligent
$7.36

-0.37 (-4.79%)

06/22/16
RAJA
06/22/16
INITIATION
Target $11
RAJA
Strong Buy
Teligent initiated with a Strong Buy at Raymond James
Raymond James analyst Elliot Wilbur initiated Teligent with a Strong Buy and $11 price target. The analyst believes the company is poised for a major growth spurt powered by its TICO product development and selection strategy that has resulted in the assembly of an enriched pipeline of long duration growth assets in high barrier to entry generic markets.
AVGR Avinger
$1.75

-0.15 (-7.89%)

07/07/16
ADAM
07/07/16
NO CHANGE
ADAM
Buy
Canaccord calls Spectranetics, Avinger buys after reimbursement announcement
Canaccord analyst Jason Mills reiterated the firm's Buy ratings on Spectranetics (SPNC ) and Avinger (AVGR) after CMS announced proposed 2017 policy and payment changes to the Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System, noting that the proposal does not include any material changes to outpatient hospital-based peripheral atherectomy payments for next year. The proposed rule for the Physician Fee Schedule will be "the final piece of the outpatient reimbursement puzzle," the analyst tells investors.
01/09/17
SPHN
01/09/17
DOWNGRADE
Target $5
SPHN
Equal Weight
Avinger downgraded to Equal Weight from Overweight at Stephens
Stephens analyst Chris Cooley downgraded Avinger to Equal Weight from Overweight after the company pre-announced below consensus Q4 operating results. While his view of the revolutionary Lumivascular platform's commercial potential remains unchanged, the analyst says "greater uncertainty" now exists associated with corporate liquidity, clouding the near-term outlook. To this end, Avinger is likely to ultimately secure financing, but the structure and terms of such a capital infusion are "unclear and arguably less favorable" following the 4Q miss, he adds. Cooley also lowered his price target on the shares to $5 from $11.
07/13/16
ADAM
07/13/16
NO CHANGE
Target $12
ADAM
Buy
Avinger price target lowered to $12 from $20 at Canaccord
Canaccord lowered its price target on Avinger to $12 from $20 after Q2 earnings and a guidance reduction the firm calls disappointing. The firm is keeping its Buy rating on Avinger shares, based on its cash position and the company's ability to drive product development, clinical evidence, and sales force expansion.
HLTH Nobilis Health
$1.60

-0.1 (-5.88%)

12/12/16
CHLM
12/12/16
DOWNGRADE
Target $2
CHLM
Hold
Nobilis Health downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum analyst Charles Haff downgraded Nobilis Health to Hold and lowered its price target to $2 from $6 citing increased risks from not transitioning to a higher in-network business mix
03/13/17
03/13/17
DOWNGRADE
Target $1.98

Nobilis Health downgraded to Neutral from Buy at PI Financial
PI Financial analyst Robert Gibson downgraded Nobilis Health to Neutral and lowered his price target for the shares to $1.98 from $7.75.
07/13/16
ADAM
07/13/16
INITIATION
Target $5
ADAM
Buy
Nobilis Health initiated with a Buy at Canaccord
Canaccord initiated Nobilis Health with a Buy, saying the recent weakness caused by a delay in its 10-Q filing is a buying opportunity. The firm sees upside to its valuation with further Athas-generated organic growth and future accretive acquisitions of surgical facilities. Canaccord has a $4.50 price target on Nobilis Health shares.
CHE Chemed
$185.65

-0.49 (-0.26%)

09/26/16
OPCO
09/26/16
NO CHANGE
Target $155
OPCO
Outperform
Oppenheimer remains a long-term buyer of Chemed
Oppenheimer analyst Michael Wiederhorn believes Chemed remains an attractive longer-term investment in the rocky healthcare universe, given its strong balance sheet/cash flow profiles, limited exposure to the ACA and a stable reimbursement profile. Further, the analyst expects the company to continue to make the most out of a challenging 2016, while 2017 should represent a return to solid organic growth levels. He reiterates an Outperform rating and $155 price target on the shares.
10/27/16
OPCO
10/27/16
NO CHANGE
Target $155
OPCO
Outperform
Chemed outlook remains 'strong,' says Oppenheimer
Oppenheimer analyst Michael Wiederhorn says Chemed's results missed estimates due to a combination of weak high-acuity results and also likely mis-modeling by the Street. Nevertheless, the analyst believes this remains a "strong" company that will look to return to normal growth levels in 2017 as the reimbursement changes are annualized. He reiterates an Outperform rating and $155 price target on the shares.
02/16/17
OPCO
02/16/17
NO CHANGE
Target $180
OPCO
Outperform
Chemed price target raised to $180 from $175 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised his price target for Chemed to $180 from $175 after the company reported in-line Q4 results and "strong" guidance. The analyst reiterates an Outperform rating on the shares as Chemed operates in two "solid businesses" with continued stable growth prospects.
07/26/16
OPCO
07/26/16
NO CHANGE
Target $155
OPCO
Outperform
Chemed price target raised to $155 from $145 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised his price target for Chemed to $155 from $145 after the company reported "solid" quarterly results as it continues to overcome the headwinds on the Vitas business. The analyst continues to favor Chemed and reiterates an Outperform rating on the shares as its core business suggests a return to its "historically steady growth" in 2017.
OVAS OvaScience

12/07/16
OPCO
12/07/16
INITIATION
OPCO
Perform
OvaScience assumed with a Perform at Oppenheimer
Oppenheimer analyst Derek Archila assumed coverage of OvaScience with a Perform rating citing a lack of revenue visibility.
BTX BioTime
$3.25

-0.21 (-6.07%)

09/23/16
LTCO
09/23/16
INITIATION
Target $6
LTCO
Buy
BioTime initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter started BioTime with a Buy rating and $6 price target. The company's restructuring story, which is roughly halfway through, should unlock shareholder value, DeGeeter tells investors in a research note.
CPSI Computer Programs
$27.95

-0.4 (-1.41%)

09/01/16
LEER
09/01/16
NO CHANGE
Target $26
LEER
Market Perform
Computer Programs price target lowered to $26 from $45 at Leerink
Leerink analyst David Larsen lowered his price target for Computer Programs to $26 from $45 as he remains cautious on the company and its ability to win significant share in 2016 and 2017. The analyst views Computer Programs' acquisition of Healthland as being one of necessity by both parties, and says that the removal of guidance is due mainly to the volatility in non-recurring business and an indication of challenged fundamentals. Further, Larsen believes Computer Programs will struggle long term in delivering earnings growth. He has a Market Perform on the shares.
01/05/17
CANT
01/05/17
INITIATION
CANT
Neutral
Computer Programs initiated with a Neutral at Cantor
01/19/17
DOTC
01/19/17
INITIATION
Target $29
DOTC
Buy
Computer Programs initiated with a Buy at Dougherty
Dougherty initiated Computer Programs with a Buy and a $29 price target.
08/05/16
RHCO
08/05/16
DOWNGRADE
RHCO
Neutral
Computer Programs downgraded on Q2 results at SunTrust
As noted earlier, SunTrust downgraded Computer Programs to Neutral from Buy. Following the company's Q2 results, analyst Sandy Draper no longer believes that the company's systems sales will improve this year, and he now says that the stability of its dividend is "in doubt." Moreover, he does not expect its business to rebound in the near-term. Target to $35 from $80.
HCA HCA Healthcare
$82.62

-1.3 (-1.55%)

01/17/17
AVON
01/17/17
UPGRADE
AVON
Outperform
HCA Holdings upgraded to Outperform from Market Perform at Avondale
03/01/17
PIPR
03/01/17
DOWNGRADE
Target $7
PIPR
Underweight
Community Health downgraded to Underweight from Neutral at Piper Jaffray
Piper Jaffray analyst Sarah James downgraded Community Health Systems to Underweight saying the 56% rally over the past four weeks is "excessive." Community Health now trades in parity with industry leader HCA Holdings (HCA) despite a weaker balance sheet, James tells investors in a research note. She believes Community's high debt levels are limiting the company's long-term growth prospects. James cut her price target for the shares to $7 from $10.
03/06/17
PIPR
03/06/17
UPGRADE
Target $147
PIPR
Overweight
Universal Health upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Sarah James upgraded Universal Health Services (UHS) to Overweight saying the valuation gap between the company and industry leader HCA Holdings (HCA) is more attractive. The analyst expects the labor shortage to resolve in the second half of 2017, driving incremental EBITDA. She raised her price target for the shares to $147 from $119.
02/01/17
FBCO
02/01/17
NO CHANGE
Target $89
FBCO
Outperform
HCA Holdings price target raised to $89 from $84 at Credit Suisse
Credit Suisse analyst Scott Fidel raised his price target for HCA Holdings to $89 from $84 after the company issued its 2017 outlook. The analyst views 2017 guidance constructively, although commentary around HCA increasing capex in light of rising competition in a number of its markets is a development to be watch closely. He reiterates an Outperform rating on the shares.
AMED Amedisys
$49.32

-0.93 (-1.85%)

01/27/17
BNCH
01/27/17
INITIATION
Target $50
BNCH
Hold
Amedisys initiated with a Hold at Benchmark
Benchmark analyst Bill Sutherland started Amedisys with a Hold rating and $50 price target.
03/02/17
OPCO
03/02/17
NO CHANGE
Target $59
OPCO
Outperform
Amedisys price target raised to $59 from $50 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised his price target for Amedisys to $59 from $50 following quarterly results. The analyst reiterates an Outperform rating on the shares.
01/17/17
CHLM
01/17/17
NO CHANGE
Target $60
CHLM
Buy
Amedisys price target raised to $60 from $48 at Craig-Hallum
Craig-Hallum analyst Bill Bonello raised his price target for Amedisys to $60 from $48, saying he expects to see "significant" multiple expansion as investors factor in the "significantly improving growth outlook." The analyst says he would buy Amedisys' shares as the operating system transition is now complete, April quality scores should be "excellent," Medicare cuts will be less severe than initially expected for 2017, and Medicare reimbursement will move from headwind to tailwind in 2018. He reiterates a Buy rating on the shares.
03/01/17
JEFF
03/01/17
NO CHANGE
Target $57
JEFF
Buy
Amedisys price target raised to $57 from $50 at Jefferies
Jefferies analyst Brian Tanquilut raised his price target for Amedisys to $57 saying he's "excited" about the company's outlook for 2017. The Q4 results foreshadow accelerating realization of benefits from Amedisys' recently-completed IT rollout that "should translate into strong earnings power and stock upside," Tanquilut tells investors in a research note. He keeps a Buy rating on the shares.
AERI Aerie Pharmaceuticals
$45.30

-2.9 (-6.02%)

03/09/17
RAJA
03/09/17
DOWNGRADE
RAJA
Market Perform
Aerie Pharmaceuticals downgraded to Market Perform on valuation at Raymond James
Raymond James analyst Elliot Wilbur downgraded Aeri Pharmaceuticals to Market Perform from Strong Buy saying shares have eclipsed his previous price target of $48 and no longer offer compelling risk/reward.
02/24/17
02/24/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Square (SQ) initiated with a Positive at Susquehanna. 2. Terex (TEX) reinstated with an Outperform at Credit Suisse. 3. Aerie Pharmaceuticals (AERI) initiated with an Outperform at Cowen. 4. Clearside Biomedical (CLSD) initiated with an Overweight at JPMorgan. 5. Park Sterling Bank (PSTB) initiated with a Hold at Brean Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/24/17
COWN
02/24/17
INITIATION
Target $70
COWN
Outperform
Aerie Pharmaceuticals initiated with an Outperform at Cowen
Cowen analyst Tyler Van Buren initiated Aerie Pharmaceuticals with an Outperform rating as he believes the company has two de-risked and approvable candidates in Phase lll. He believes the company will be a prime consolidation candidate. Van Buren has a $70 price target on Aerie Pharmaceuticals shares.
02/17/17
02/17/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Square (SQ) initiated with a Buy at Citi by analyst Peter Christiansen, who said the company has the capability of "redefining" brick-and-mortar payments and commerce enablement. 2. Aerie Pharmaceuticals (AERI) initiated by Roth Capital analyst Sa'ar Yaniv with a Buy rating and $69 price target as he expects Rhopressa and Roclatan approval in 2018 and 2019. 3. Aegis analyst Chris Kapsch initiated Albemarle (ALB) with a Buy and a $108 price target, calling it a "must-own" stock over at least the next couple years. 4. Arch Coal (ARCH) initiated with a Buy at Jefferies by analyst Christopher LaFemina, citing the company's portfolio of "low-cost" U.S. coal assets and a "clean" balance sheet. 5. Piper Jaffray analyst Erinn Murphy assumed coverage of Nordstrom (JWN) with a Neutral rating and $41 price target, saying she believes price transparency may continue to hinder the company's results. Murphy also assumed coverage of J.C. Penney (JCP) with a Neutral rating and $8 price target, noting worries about the underlying secular pressure Amazon.com (AMZN) is putting on the industry, and assumed coverage of Kohl's (KSS) with a Neutral rating and $40 price target, as she believes earnings growth will be tough amid the current environment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CUR Neuralstem
$5.35

-0.36 (-6.30%)

08/29/16
08/29/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Sell at Axiom by analyst Victor Anthony, who set an $80 price target on shares of the streaming service operator. The company's is seeing rising competition and diminishing pricing power, Anthony tells investors in a research note. He adds that rising content costs will pressure Netflix's ability to meet Street estimates. 2. Invuity (IVTY) initiated with a Buy rating and $25 price target by Craig-Hallum analyst Charles Haff, who believes the company's surgical lighting products offer higher quality resolution and are safer and more effective than the current standard of care in minimally-invasive procedures. 3. Recro Pharma (REPH) initiated by Janney Capital analyst Ken Trbovich with a Buy rating and $21 fair value estimate. 4. Neuralstem (CUR) initiated by Roth Capital analyst Joseph Pantginis with a Buy rating and $1.20 price target. 5. At Home Group (HOME) initiated with an Outperform rating at William Blair and with a Buy rating and $20 price target at Jefferies. To see The Fly's full Street Research coverage, Reference Link
10/04/16
BMUR
10/04/16
INITIATION
Target $4
BMUR
Buy
Neuralstem assumed with a Buy at Brean Capital
Brean Capital analyst Jason Wittes assumed coverage of Neuralstem with a Buy rating and $4 price target.
08/29/16
ROTH
08/29/16
INITIATION
Target $1.2
ROTH
Buy
Neuralstem initiated with a Buy at Roth Capital
Roth Capital analyst Joseph Pantginis started Neuralstem with a Buy rating and $1.20 price target.
11/07/16
AGIS
11/07/16
INITIATION
Target $2.25
AGIS
Buy
Neuralstem initiated with a Buy at Aegis
Aegis analyst Jason Wittes initiated Neuralstem with Buy and a $2.25 price target.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.